-
Yifan Pharmaceutical’s F-627 Approved by European Commission for Marketing in EU
•
Yifan Pharmaceutical Co., Ltd (SHE: 002019), a Chinese pharmaceutical company, has announced that its subsidiary Evive Biotech Ltd’s drug Ryzneuta (efbemalenograstim alfa, F-627) has received marketing approval from the European Commission (EC) in the European Union (EU), following a recommendation by the European Medicines Agency’s Committee for Medicinal Products for…
-
OBiO Technology Partners with Saierxin Bio to Support Treg Cell Therapy Development
•
OBiO Technology (Shanghai) Co., Ltd (SHA: 688238), a Chinese Contract Research Organization (CRO) specializing in gene therapy, has entered into a strategic partnership with Shanghai Saierxin Biomedical Technology Co., Ltd. Under the terms of the agreement, OBiO will offer non-registered clinical trial sample preparation and testing services for Saierxin Bio’s…
-
Grand Pharma Receives NMPA Approval for Global Phase III Study of RDC ITM-11 in GEP-NETs
•
Grand Pharmaceutical Group Ltd (HKG: 0512), a leading pharmaceutical company based in China, has announced that it has received approval from the National Medical Products Administration (NMPA) to conduct the COMPOSE study. This is a prospective, randomized, controlled, open-label, global multi-center Phase III study designed to assess the efficacy, safety,…
-
Jenscare Scientific Completes Enrollment in Clinical Study for Mitral Valve Repair System
•
Jenscare Scientific Co., Ltd (HKG: 9877), a leading structural heart disease device manufacturer headquartered in Ningbo, has announced the successful completion of patient enrollment in a confirmatory study for its flagship product, the JensClip transcatheter mitral valve repair and clamping system. The system is designed to address severe mitral regurgitation,…
-
Zhejiang Dian Diagnostics Partners with Haihe Laboratory to Advance Hematology Diagnostics
•
Zhejiang Dian Diagnostics Co., Ltd (SHE: 300244), a company based in China, has entered into a strategic partnership with the Haihe Laboratory of Cell Ecosystem under the China Academy of Medical Sciences. The collaboration aims to drive research translation, standardize disease diagnosis and treatment, advance digital healthcare, and enhance discipline…
-
Golden Leaf Med Tec Secures Series D Funding to Advance Hypertension and Diabetes Treatments
•
Shanghai Golden Leaf Med Tec Co., Ltd, a specialist in interventional treatments based in China, has reportedly secured “hundreds of millions” of renminbi in a Series D financing round. The round was led by ZhongPing Capital, with participation from Shanghai Healthcare Capital, Dingxin Capital, and Morning Spring Venture. The funds…
-
Joincare Pharmaceuticals Secures Rights to Bayer’s Respiratory Drug in China
•
Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380), a Chinese pharmaceutical company, has announced a significant licensing agreement with German healthcare giant Bayer. Under the terms of this agreement, Joincare has obtained development, commercialization, and manufacturing rights to Bayer’s small-molecule inhibitor in the respiratory field within China. The financial specifics…
-
AriBio Expands Alzheimer’s Drug AR1001 Licensing Deal with Samjin to Include China
•
AriBio Co., Ltd, a South Korea-based pharmaceutical company, has announced an expansion of its previous licensing agreement with Samjin Pharmaceutical (KRX: 005500) to include the China market for its Alzheimer’s disease drug candidate, AR1001. The new deal, which grants exclusive marketing rights to the drug in China, is valued at…
